Table 4.
Results of multivariate Cox regression analysis for LPFS, PFS, and OS
| Factor | Regression coefficient | Wald value | P value | RR value | 95% CI |
|---|---|---|---|---|---|
| LPFS | |||||
| Size of largest brain metastasis | 0.764 | 7.566 | 0.006 | 2.146 | 1.245–3.698 |
| Extracranial metastasis or uncontrolled primary tumor | 1.566 | 5.377 | 0.020 | 4.788 | 1.274–17.990 |
| Erlotinib medication | −2.094 | 13.882 | 0.000 | 0.123 | 0.041–0.371 |
| Chemotherapy | −1.123 | 6.001 | 0.014 | 0.325 | 0.132–0.799 |
| PFS | |||||
| Extracranial metastasis or uncontrolled primary tumor | 3.094 | 11.882 | 0.001 | 22.062 | 3.799–128.124 |
| Erlotinib medication | −1.297 | 7.191 | 0.007 | 0.273 | 0.106–0.705 |
| OS | |||||
| Extracranial metastasis or uncontrolled primary tumor | 1.332 | 4.145 | 0.042 | 3.787 | 1.051–13.647 |
| Erlotinib medication | −1.012 | 3.843 | 0.050 | 0.364 | 0.132–1.000 |
| Chemotherapy | −1.296 | 8.605 | 0.003 | 0.274 | 0.115–0.650 |
Abbreviations: LPFS, local progression-free survival; CI, confidence interval; OS, overall survival; PFS, progression-free survival; RR, response rate.